I think the case for Prurisol for psoriasis is an even stronger argument than B-OM for bypassing P3 due to the decades of safety seen from the parent drug, the enormous amount of data to be received from the P2b by the addition of the quality of life questionnaire, lack of any serious side effects, the fact it is already on the FDA 505(b)(2) program, and the ability alone to greatly alleviate or stop the worst symptom of all, the itching, even if it is shows (which I don't think it will) not doing that much to cure the psoriasis.

Bottom line: We have 2 solid winners in P and B and when K finally is formulated into a pill that will surge forward into another major winner.